Physician profile
Alex Wright
NPI 1407296999
$3,482.16
in general payments reported to CMS, 2019-2025
27 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $215 · 2021: $640 · 2022: $595 · 2023: $310 · 2024: $224 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.06 | 2021-2024 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $443.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.38 | 2019-2023 | Jardiance |
| Pfizer INC. | $273.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $227.31 | 2019-2021 | |
| Tris Pharma INC | $204.45 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Lilly USA, LLC | $194.50 | 2019-2022 | |
| Amgen INC. | $193.67 | 2019-2023 | Otezla, Repatha, Evenity |
| Corium, LLC | $175.26 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $134.81 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $94.25 | 2021-2023 | |
| Allergan, INC. | $92.18 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.22 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $80.59 | 2019-2024 | |
| Abbott Laboratories | $50.94 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $50.29 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $49.87 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $44.73 | 2019-2021 | |
| Astellas Pharma US INC | $32.86 | 2022-2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $25.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $22.11 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $21.95 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.19 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.18 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $12.25 | 2021 | |
| Gilead Sciences, INC. | $12.06 | 2019 | |
| Adlon Therapeutics L.P. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.